Associations between genetic HPV 16 diversity and cervical cancer prognosis
PLOS One · 2025
DOI: 10.1371/journal.pone.0308895 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Patrícia Patury und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Department, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Human papillomavirus 16, Papillomavirus Infections, Genetic Variation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cervical cancer (CC) arises as a result of chronic and persistent female infection by different oncogenic human papillomaviruses (HPV). The incidence of this disease is still high in developing countries, such as Brazil, where diagnosis is often made in advanced stages. HPV 16 is the most common Papillomavirus genotype in CC worldwide. Studies regarding the association of different HPV 16 lineages with overall and disease-free CC survival rates can contribute to further understanding the behavior of different HPV 16 lineages concerning the prognosis of CC cases.
Objective
To assess the CC prognosis of patients treated in a Brazilian institution concerning HPV16 lineages.
Methods
Data were obtained from a prospective cohort of 334 patients with CC recruited between July 2011 and March 2014 and treated at the Brazilian National Cancer Institute (INCA), in Rio de Janeiro, Brazil. HPV 16 lineages were identified in tumor tissue samples. Genetic HPV 16 diversity comprised 218 cases of lineage A, 10 of lineage B, 10 of lineage C, and 96 of lineage D. In addition to HPV 16 lineages, age, histopathological type, staging, and treatment completion were evaluated as predictors of CC prognosis.
Results
The median patient age was 48 years. The most common histopathological type was squamous cell carcinoma (82.3%), followed by adenocarcinoma. Locally advanced disease staging was the most frequently detected, represented by similar stage II and III percentages (36.2% and 37.7%), followed by initial stage I (19.2%) and stage IV (6.9%). Two hundred two patients completed CC treatment. Age, histological type, staging, and treatment completion were associated with a higher risk of death, which was not observed for the HPV 16 lineage variable. With regard to age, an increase in each year of life led to approximately a 1% increase in the risk of death. Other histopathological types (poorly differentiated carcinoma, adenosquamous, neuroendocrine, and sarcoma) were associated with a higher risk of death compared with adenocarcinoma. Patients diagnosed in advanced stages exhibited a higher risk of death, and those who did not complete treatment exhibited an over 2-fold increased risk of death.
Conclusion
This study found no associations between HPV 16 lineages A, B, C, and D and CC prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gynecologic Oncology Department, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Clinical and Surgical Care of Women, National Institute of Women, Children and Adolescents Health Fernandes Figueira, Rio de Janeiro, Rio de Janeiro, Brazil.
- Tumoral Genetics and Virology Program, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Physiotherapy, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil.
- Division of Surveillance and Situation Analysis, Brazilian National Cancer Institute (INCA), Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Female Endocrinology, National Institute of Women, Children and Adolescents Health Fernandes Figueira, Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Miguel Angelo Martins Moreira, Nádia R C Kappaun
Zitieren
APA
Patury, P., Russomano, F. B., Moreira, M. A. M., Kappaun, N. R. C., de Almeida, L. M., Carvalho, R. B. M., & Martins, L. F. L. (2025). Associations between genetic HPV 16 diversity and cervical cancer prognosis. PLOS One. https://doi.org/10.1371/journal.pone.0308895
Vancouver
Patury P, Russomano FB, Moreira MAM, Kappaun NRC, de Almeida LM, Carvalho RBM, et al. Associations between genetic HPV 16 diversity and cervical cancer prognosis. PLOS One. 2025. doi:10.1371/journal.pone.0308895
BibTeX
@article{Patury2025,
author = {Patury, Patrícia and Russomano, Fabio B and Moreira, Miguel Angelo Martins and Kappaun, Nádia R C and de Almeida, Liz Maria and Carvalho, Raquel B M and Martins, Luís Felipe L},
title = {Associations between genetic HPV 16 diversity and cervical cancer prognosis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0308895}
}
EUVIMED